Cargando…
Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China
The B.1.617.2 (Delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has contributed to a new increment in cases across the globe. We conducted a prospective follow-up of COVID-19 cases to explore the recurrence and potential propagation risk of the Delta variant and dis...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Instituto de Medicina Tropical de São Paulo
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084466/ https://www.ncbi.nlm.nih.gov/pubmed/35544909 http://dx.doi.org/10.1590/S1678-9946202264031 |
_version_ | 1784703618698444800 |
---|---|
author | Wu, Qilin Wang, Chang Jing, Qinlong Lu, Jianyun Liang, Boheng Liu, Lan Wu, Jinyi Yu, Qing Deng, Xilong Zhang, Zhoubin |
author_facet | Wu, Qilin Wang, Chang Jing, Qinlong Lu, Jianyun Liang, Boheng Liu, Lan Wu, Jinyi Yu, Qing Deng, Xilong Zhang, Zhoubin |
author_sort | Wu, Qilin |
collection | PubMed |
description | The B.1.617.2 (Delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has contributed to a new increment in cases across the globe. We conducted a prospective follow-up of COVID-19 cases to explore the recurrence and potential propagation risk of the Delta variant and discuss potential explanations for the infection recurrence. A prospective, non-interventional follow-up of discharged patients who had SARS-CoV-2 infections by the Delta variant in Guangdong, China, from May 2021 to June 2021 was conducted. The subjects were asked to complete a physical health examination and undergo nucleic acid testing and antibody detection for the laboratory diagnosis of COVID-19. In total, 20.33% (25/123) of patients exhibited recurrent positive results after discharge. All patients with infection recurrence were asymptomatic and showed no abnormalities in the pulmonary computed tomography. The time from discharge to the recurrent positive testing was usually between 1-33 days, with a mean time of 9.36 days. The cycle threshold from the real-time polymerase chain reaction assay that detected the recurrence of positivity ranged from 27.48 to 39.00, with an average of 35.30. The proportion of vaccination in the non-recurrent group was higher than that in the recurrently positive group (26% vs. 4%; χ(2) = 7.902; P < 0.05). Two months after discharge, the most common symptom was hair loss and 59.6% of patients had no long-term symptoms at all. It is possible for the Delta variant SARS-CoV-2 patients after discharge to show recurrent positive results of nucleic acid detection; however, there is a low risk of continuous community transmission. Both, the physical and mental quality of life of discharged patients were significantly affected. Our results suggest that it makes sense to implement mass vaccination against the Delta variant of SARS-CoV-2. |
format | Online Article Text |
id | pubmed-9084466 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Instituto de Medicina Tropical de São Paulo |
record_format | MEDLINE/PubMed |
spelling | pubmed-90844662022-05-12 Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China Wu, Qilin Wang, Chang Jing, Qinlong Lu, Jianyun Liang, Boheng Liu, Lan Wu, Jinyi Yu, Qing Deng, Xilong Zhang, Zhoubin Rev Inst Med Trop Sao Paulo Original Article The B.1.617.2 (Delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has contributed to a new increment in cases across the globe. We conducted a prospective follow-up of COVID-19 cases to explore the recurrence and potential propagation risk of the Delta variant and discuss potential explanations for the infection recurrence. A prospective, non-interventional follow-up of discharged patients who had SARS-CoV-2 infections by the Delta variant in Guangdong, China, from May 2021 to June 2021 was conducted. The subjects were asked to complete a physical health examination and undergo nucleic acid testing and antibody detection for the laboratory diagnosis of COVID-19. In total, 20.33% (25/123) of patients exhibited recurrent positive results after discharge. All patients with infection recurrence were asymptomatic and showed no abnormalities in the pulmonary computed tomography. The time from discharge to the recurrent positive testing was usually between 1-33 days, with a mean time of 9.36 days. The cycle threshold from the real-time polymerase chain reaction assay that detected the recurrence of positivity ranged from 27.48 to 39.00, with an average of 35.30. The proportion of vaccination in the non-recurrent group was higher than that in the recurrently positive group (26% vs. 4%; χ(2) = 7.902; P < 0.05). Two months after discharge, the most common symptom was hair loss and 59.6% of patients had no long-term symptoms at all. It is possible for the Delta variant SARS-CoV-2 patients after discharge to show recurrent positive results of nucleic acid detection; however, there is a low risk of continuous community transmission. Both, the physical and mental quality of life of discharged patients were significantly affected. Our results suggest that it makes sense to implement mass vaccination against the Delta variant of SARS-CoV-2. Instituto de Medicina Tropical de São Paulo 2022-05-06 /pmc/articles/PMC9084466/ /pubmed/35544909 http://dx.doi.org/10.1590/S1678-9946202264031 Text en https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Wu, Qilin Wang, Chang Jing, Qinlong Lu, Jianyun Liang, Boheng Liu, Lan Wu, Jinyi Yu, Qing Deng, Xilong Zhang, Zhoubin Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China |
title | Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China |
title_full | Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China |
title_fullStr | Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China |
title_full_unstemmed | Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China |
title_short | Follow-up of patients with COVID-19 by the Delta variant after hospital discharge in Guangzhou, Guandong, China |
title_sort | follow-up of patients with covid-19 by the delta variant after hospital discharge in guangzhou, guandong, china |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084466/ https://www.ncbi.nlm.nih.gov/pubmed/35544909 http://dx.doi.org/10.1590/S1678-9946202264031 |
work_keys_str_mv | AT wuqilin followupofpatientswithcovid19bythedeltavariantafterhospitaldischargeinguangzhouguandongchina AT wangchang followupofpatientswithcovid19bythedeltavariantafterhospitaldischargeinguangzhouguandongchina AT jingqinlong followupofpatientswithcovid19bythedeltavariantafterhospitaldischargeinguangzhouguandongchina AT lujianyun followupofpatientswithcovid19bythedeltavariantafterhospitaldischargeinguangzhouguandongchina AT liangboheng followupofpatientswithcovid19bythedeltavariantafterhospitaldischargeinguangzhouguandongchina AT liulan followupofpatientswithcovid19bythedeltavariantafterhospitaldischargeinguangzhouguandongchina AT wujinyi followupofpatientswithcovid19bythedeltavariantafterhospitaldischargeinguangzhouguandongchina AT yuqing followupofpatientswithcovid19bythedeltavariantafterhospitaldischargeinguangzhouguandongchina AT dengxilong followupofpatientswithcovid19bythedeltavariantafterhospitaldischargeinguangzhouguandongchina AT zhangzhoubin followupofpatientswithcovid19bythedeltavariantafterhospitaldischargeinguangzhouguandongchina |